報價延遲最少15分鐘:2024/06/25 02:54 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.81 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.55/-1.29
|
|
企業價值
272.73M
|
| 資產負債 |
|
每股賬面淨值
1.98
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
5.90M
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/06/25 02:54 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA. |